Literature DB >> 32817227

Testing of In Vitro Susceptibility of Neisseria gonorrhoeae to Azithromycin: Comparison of Disk Diffusion and Reference Agar Dilution Methods.

Ricardo Gianecini1, Lucia Irazu2, Marcelo Rodríguez2, Paula Cristaldo1, Claudia Oviedo1, Marisa Turco3, Veronica Rodrigo3, Liliana Fernández Canigia4, Ana Schneider4, Liliana Guelfand5, Laura Scocozza5, Patricia Galarza6.   

Abstract

Azithromycin in combination with ceftriaxone is recommended as the first-line treatment for uncomplicated gonorrhea in many countries. Therefore, monitoring of azithromycin susceptibility of Neisseria gonorrhoeae isolates is essential. In 2019, the Clinical and Laboratory Standards Institute (CLSI) listed the MIC breakpoint for a susceptible-only category to azithromycin, but breakpoints for disk diffusion are not yet available. In this study, we evaluated the usefulness of disk diffusion for testing the susceptibility of N. gonorrhoeae isolates to azithromycin. A total of 189 clinical isolates susceptible and nonsusceptible to azithromycin were used. Agar dilution MICs were correlated with inhibition zone diameters of azithromycin disks (15-μg) manufactured by BBL and Oxoid. In addition, an interlaboratory study involving two clinical microbiology laboratories was conducted. There was a strong correlation between disk diffusion and agar dilution for BBL disks (r = -0.74; P < 0.001) and Oxoid disks (r = -0.75; P < 0.001). Using a zone diameter breakpoint of ≥27 mm (susceptible) and ≤26 mm (nonsusceptible) yielded good separation between susceptible and nonsusceptible isolates and the least number of discrepancies. Compared to agar dilution, disk diffusion showed high agreement and kappa values of 95.2% and 0.899 (P < 0.001) for BBL disks and 96.8% and 0.933 (P < 0.001) for Oxoid disks, respectively. Major and very major discrepancies were observed in isolates with azithromycin MICs (1 and 2 μg/ml, respectively) near to the breakpoint. These data illustrate that disk diffusion could be a reliable method in clinical laboratories to test susceptibility to azithromycin in N. gonorrhoeae isolates.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Neisseria gonorrhoeaezzm321990; azithromycin; disk diffusion

Year:  2020        PMID: 32817227      PMCID: PMC7587106          DOI: 10.1128/JCM.01398-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization.

Authors:  Magnus Unemo; Daniel Golparian; Leonor Sánchez-Busó; Yonatan Grad; Susanne Jacobsson; Makoto Ohnishi; Monica M Lahra; Athena Limnios; Aleksandra E Sikora; Teodora Wi; Simon R Harris
Journal:  J Antimicrob Chemother       Date:  2016-07-17       Impact factor: 5.790

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea.

Authors:  Helen Fifer; Usha Natarajan; Lucy Jones; Sarah Alexander; Gwenda Hughes; Daniel Golparian; Magnus Unemo
Journal:  N Engl J Med       Date:  2016-06-23       Impact factor: 91.245

4.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 5.  World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts.

Authors:  Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

6.  WHONET: an information system for monitoring antimicrobial resistance.

Authors:  T F O'Brien; J M Stelling
Journal:  Emerg Infect Dis       Date:  1995 Apr-Jun       Impact factor: 6.883

7.  Accuracy and reproducibility of the Etest to detect drug-resistant Neisseria gonorrhoeae to contemporary treatment.

Authors:  John R Papp; Marie-Claire Rowlinson; Norman P O'Connor; Jason Wholehan; Jafar H Razeq; Anita Glennen; Dapne Ware; Peter C Iwen; Lillian V Lee; Celia Hagan
Journal:  J Med Microbiol       Date:  2017-12-08       Impact factor: 2.472

8.  Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales.

Authors:  S A Chisholm; T J Neal; A B Alawattegama; H D L Birley; R A Howe; C A Ison
Journal:  J Antimicrob Chemother       Date:  2009-05-25       Impact factor: 5.790

9.  Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action.

Authors:  Teodora Wi; Monica M Lahra; Francis Ndowa; Manju Bala; Jo-Anne R Dillon; Pilar Ramon-Pardo; Sergey R Eremin; Gail Bolan; Magnus Unemo
Journal:  PLoS Med       Date:  2017-07-07       Impact factor: 11.069

10.  2012 European guideline on the diagnosis and treatment of gonorrhoea in adults.

Authors:  C Bignell; M Unemo
Journal:  Int J STD AIDS       Date:  2013-02       Impact factor: 1.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.